ZÃ¼rich-Schlieren, Switzerland, 09 December, 2014. Molecular Partners announced today that Janssen Biotech, Inc. (â€œJanssenâ€) has exercised an option to secure exclusive rights to a multi-specific DARPin program. As a compensation for the option exercise, Molecular Partners will receive a milestone payment of USD 2 million.
All posts by Ashley Voigt
Zurich-Schlieren, December 5, 2014. Molecular Partners AG announces that the total offer size of the initial public offering (â€œIPOâ€) amounts to CHF 106.2 million, of which gross proceeds from the primary shares issued are CHF 104.1 million. The Joint Bookrunners of Molecular Partners’ IPO have partially exercised the over-allotment option yesterday at the offer price of CHF 22.40 per share.
Zurich-Schlieren, November 4, 2014. Molecular Partners AG has successfully re-launched its Initial Public Offering (IPO). Due to strong interest and demand from both international and Swiss institutional and private investors, Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday, Monday, 5pm CET.
Zurich-Schlieren, November 3, 2014. Molecular Partners AG announced today to resume the bookbuilding process for its Initial Public Offering (IPO) on the SIX Swiss Exchange on revised transaction terms. The price for the offered registered shares with a nominal value of CHF0.10 each has been fixed at CHF22.4 per share, which implies a post money equity value on a fully-diluted basis of approximately CHF485 million (prior to exercise of the over-allotment option).
Zurich-Schlieren, October 8, 2014. Molecular Partners AG, a clinical-stage biopharmaceutical company focused on the discovery and development of a pioneering class of protein therapeutics called DARPinsâ„¢ for the treatment of severe or life-threatening diseases, announced today the launch of its initial public offering (IPO) on SIX Swiss Exchange with the publication of the offering and listing memorandum and the start of the bookbuilding process.
Molecular Partners AG announced today results from the Allergan-sponsored, double-masked stage 3 phase 2 study of the DARPin abicipar pegol, for wet age-related macular degeneration (AMD).
Molecular Partners AG and Roche (SIX: RO, ROG; OTCQX: RHHBY) have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Molecular Partners’ DARPin™ biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
Molecular Partners announced today that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME)
Molecular Partners and Boehringer Ingelheim’s biopharmaceutical contract manufacturing business have entered into a strategic manufacturing collaboration.
Molecular Partners AG today announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPinÂ® products for the treatment of immunological diseases.